|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Esperion Therapeutics (NASDAQ: ESPR) through any online brokerage.
The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Credit Suisse on January 14, 2022. The analyst firm set a price target for 6.00 expecting ESPR to rise to within 12 months (a possible 47.42% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Esperion Therapeutics (NASDAQ: ESPR) is $4.07 last updated Fri Jan 28 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Esperion Therapeutics.
Esperion Therapeutics’s $Q4 earnings are confirmed for after-market on February 22, 2022.
There is no upcoming split for Esperion Therapeutics.
Esperion Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.